Recent news on Xopenex

Medicare To Cut Reimbursement Levels For Sepracor's Asthma Drug ...  -  May 21, 2007
Insurance News Net,The Centers for Medicare & Medicaid Services will assign the same temporary reimbursement codes to all forms of albuterol, including Xopenex.

Adrian Adams named new CEO of Sepracor  -  May 16, 2007
Milwaukee Business Journal,Other than Lunesta, the company also sells bronchitis treatments Xopenex HFA and Xopenex. Sepracor announced last month that it would begin selling Brovana,

Sepracor Inc. Is Losing Ground After The Bell  -  May 18, 2007
Trading Markets,The Centers for Medicare & Medicaid Services announced Friday that it plans to cut reimbursement levels for Sepracor's asthma drug Xopenex, to the level of

Sector Snap: Drug Makers  -  May 21, 2007
Forbes,Shares fell nearly 11 percent Friday on fears that Medicare will slash reimbursement of the company's asthma drug Xopenex to that of a generic medication.

Sector Snap: Drug Makers  -  May 21, 2007
Euro2day,Shares fell nearly 11 percent Friday on fears that Medicare will slash reimbursement of the company''s asthma drug Xopenex to that of a generic medication.

Drugstores face scrutiny in race for clinics  -  May 20, 2007
Chicago Tribune,Estes, who was fatigued with congestion, was relieved that she could be helped by the asthma medication Xopenex, a common medicine prescribed to open

US Stocks Rise for 7th Week on Stake Disclosures, Takeovers  -  May 19, 2007
BloombergSepracor slumped 13 percent to $46.70 on concern the company would be paid less by the US Medicare program for the asthma drug Xopenex, its top-selling

Wellness News & Events  -  Apr 26, 2007
The Salinas Californian,As a result, a member's co-pay for CFC-free Xopenex now ranges from $5 to $10, depending on the member's benefit plan. April is volunteer month,

Management Changes - Weekly Recap  -  May 18, 2007
Trading Markets,For the first quarter, Sepracor profit more than doubled to $22.5 million or $0.19 per share, on strong sales of the company's asthma drug Xopenex.

Midday Leaders & Laggards: Nasdaq 100  -  May 18, 2007
Houston Chronicle,Web site indicates changes to reimbursement for Sepracor's asthma drug Xopenex, which could lower the selling price of the drug as soon as July 1.

Largest $ Movers of Note - StreetInsider.com - 05/18/2007  -  May 18, 2007
StreetInsider.com (subscription),Sepracor, Inc. (Nasdaq: SEPR) -$7.54; Down on speculation Medicare will cut reimbursement payments for the companys' asthma drug, Xopenex.

Analyst downgrades 5-18-07: ADSK, MO, SEPR, THC and VCLK  -  May 18, 2007
Blogging StocksSummer Street downgraded Sepracor (NASDAQ: SEPR) to Sell from Neutral after the HCPCS website indicated Xopenex and Albuterol will have the same code as of

Drug maker names CEO  -  May 16, 2007
Worcester Telegram,...a result built on the sales of Lunesta, an insomnia treatment and one of the nation’s most heavily promoted drugs, and the asthma treatment Xopenex.

Sepracor Names Adams CEO  -  May 15, 2007
TheStreet.comThe company also gets a large part of its revenue from Xopenex, a bronchial inhaler solution. In April, Sepracor started selling a new drug called Brovana

Sepracor’s profit doubles  -  Apr 25, 2007
Worcester Telegram,Xopenex, the asthma drug, generated $173 million in sales, up 24 percent from a year earlier. The company spent 17 percent less on research and development

Sepracor Announces First Quarter 2007 Results  -  Apr 24, 2007
PharmaLive.com (press release),XOPENEX(R) brand levalbuterol HCl Inhalation Solution -- XOPENEX Inhalation Solution is a short-acting beta-agonist indicated for the treatment or

Brovana Inhalation Solution Now Available by Prescription for ...  -  Apr 11, 2007
PharmaLive.com (press release),Sepracor's sales force has marketed XOPENEX brand levalbuterol HCl Inhalation Solution, which is a short-acting beta-agonist indicated for the treatment or

Wellness News & Events  -  Apr 19, 2007
The Salinas Californian,As a result, a member's co-pay for CFC-free Xopenex ranges from $5 to $10, depending on the member's co-pay benefit. April is volunteer month and The Park

Insurer reduces fees to asthmatics for inhaler from Marlboro company  -  Apr 13, 2007
Worcester Telegram,Under the agreement announced yesterday, Sepracor’s Xopenex, one of four CFC-free inhalers introduced in response to the ban, will cost as little as $5 for

UnitedHealthcare Lowers Copayment for Chlorofluorocarbon-Free ...  -  Apr 15, 2007
dBusinessNews Minneapolis (press release),UHPS has moved Xopenex HFA to Tier 1 – the lowest copay tier – on its prescription drug list so that commercial members have an affordable, effective way to

Welch: Times Co. had no interest in selling Globe  -  Apr 12, 2007
Boston Globe,Sepracor's Xopenex, one of four CFC-free inhalers, will cost as little as $5 for UnitedHealth patients. Xopenex generated $41 million last year,

SC residents with asthma get inhaler price break  -  Apr 17, 2007
Santa Cruz Sentinel,UnitedHealthcare, parent company of insurer PacifiCare, has lowered the co-payment for chlorofluorocarbon-free Xopenex inhalers for its members.

Sepracor launches respiratory drug  -  Apr 11, 2007
Boston Globe,..."The launch of Brovana expands our respiratory portfolio of products, which includes Xopenex Inhalation Solution and Xopenex HFA metered-dose inhaler,

Sepracor launches Brovana to market  -  Apr 11, 2007
Boston Business Journal,The other treatments are: Insomnia treatment Lunesta, and bronchitis treatments Xopenex HFA and Xopenex. Sepracor has also developed at least two drugs

Sepracor Says BROVANA Inhalation Solution Now Available By ...  -  Apr 11, 2007
Trading Markets,The company added that the launch of BROVANA expands its respiratory portfolio of products, which includes XOPENEX Inhalation Solution and XOPENEX HFA

UnitedHealth cuts co-pay on asthma inhaler  -  Apr 13, 2007
United Press InternationalThe insurer said its pharmacy benefit manager UnitedHealth Pharmaceutical Solutions has reclassified its chlorofluorocarbon-free, asthma inhaler Xopenex to

German firm's unit sues Sepracor over drug patent  -  27 Mar 2007
Boston Globe,Marlborough-based Sepracor, maker of the Lunesta sleeping pill and Xopenex asthma treatment, plans to begin selling Brovana in the second quarter,

High hopes, steep fall  -  27 Mar 2007
Boston Globe,Its Xopenex asthma drug generated sales roughly equal to Lunesta revenue last year, and other products are under development.

Daily Option Update - March 14, 2007  -  Mar 14, 2007
Blogging StocksSEPR markets Lunesta, a prescription sleep aid and Xopenex, a treatment to prevent bronchospasm. SEPR is down .67 to $48.15. Dow Jones reported "The FDA

Sepracor Announces Senior Management Changes  -  Mar 2, 2007
PharmaLive.com (press release),Lunesta and Xopenex are registered trademarks of Sepracor. For a copy of this release or any recent release, visit Sepracor's web site at www.sepracor.com.

Sepracor "outperform"  -  Mar 8, 2007
newratings.comThe alteration in the CMS reimbursement for Xopenex is likely to either have a marginal adverse impact or no impact at all on the company’s performance

Sepracor Names New COO  -  Mar 2, 2007
TheStreet.comSepracor makes the insomnia drug Lunesta and asthma drug Xopenex. The announcement came after the market closed Thursday. O'Shea, 57, had been president and

Generic-Drug Firms Impatient for Patents  -  Mar 12, 2007
Barron's (subscription)Of the 36 ongoing and potential patent challenges we profiled, Sepracor's Xopenex represents one of the largest portions of the defender's 2007 estimated

Sepracor Announces Senior Management Changes  -  Mar 1, 2007
Business Wire (press release),...infrastructure of the Company, which has resulted in the success of two major franchises, XOPENEX ® brand levalbuterol and LUNESTA ® brand eszopiclone.

Sepracor Announces Fourth Quarter and Full Year 2006 Results  -  Jan 31, 2007
Business Wire (press release),XOPENEX ® brand levalbuterol HCl Inhalation Solution — XOPENEX Inhalation Solution is a short-acting beta-agonist indicated for the treatment or prevention

Sepracor Announces Fourth Quarter and Full Year 2006 Results  -  Jan 31, 2007
Genetic Engineering News (press release),Patients administered XOPENEX Inhalation Solution received fewer total nebulizations during their hospital stay versus patients administered albuterol

Sepracor Falls on 2007 Outlook  -  Jan 31, 2007
Forbes,While Xopenex sales accounted for $200.8 million in revenue, Lunesta sales only rose 2 percent to $148 million in the latest quarter.

Health briefs  -  Feb 3, 2007
Chicago Sun-Times,Consumers shouldn't use Sepracor's Xopenex asthma inhalers, as there isn't any ''compelling evidence'' they work better than older, cheaper products,

Soft Outlook Hits Sepracor  -  Jan 31, 2007
TheStreet.comTrading volume was five times the average for the company that makes the insomnia drug Lunesta and the asthma drug Xopenex.

UPDATE 2-Sepracor profit up, but rev forecast hurts stock  -  Jan 31, 2007
Reuters..."The healthy top-line beat is entirely attributable to above expectations of Xopenex sales," Adam Greene, an analyst at JPMorgan, wrote in a research note.

Sepracor 4Q Profit Nearly Triples  -  Jan 31, 2007
Forbes,The company's line of Xopenex asthma medications accounted for $200.8 million in sales, and sleep aid Lunesta accounted for $148 million in the latest

Business briefs  -  Feb 1, 2007
Worcester Telegram,...after rising 40 percent in the third quarter — overshadowed a 27 percent jump in sales of the asthma treatment Xopenex, Sepracor’s biggest product.

Nurses at Tufts-NEMC ratify two-year contract  -  Feb 2, 2007
Boston Globe,Separately, the advocacy group Public Citizen said Sepracor's Xopenex asthma inhalers should not be used as there is no "compelling evidence" they work

Google easily beats analysts' forecasts  -  Feb 1, 2007
Boston Globe,...stating that sluggish sales of the sleep aid Lunesta were hidden by lower marketing costs and a boost in sales of Xopenex asthma medication sales. (AP)

Health : Levalbuterol Is No More Effective Than Older, Cheaper ...  -  Feb 2, 2007
All American Patriots (press release),1, 2007 -- WASHINGTON, DC –Levalbuterol HFA (Xopenex HFA) inhalers are no more effective than older, less expensive drugs used to treat asthma and other

Sepracor shares up on CMS analysis  -  Dec 21, 2006
BusinessWeekThe Centers for Medicare and Medicaid Services said it will conduct an analysis of nebulized levalbuterol, which includes the company's Xopenex inhalable

Ahead of the Bell: Sepracor  -  Dec 22, 2006
BusinessWeekThe Centers for Medicare and Medicaid Services plans to review its guidelines for when nebulized levalbuterol, including the company's Xopenex inhalable

Zacks Analyst Blog Highlights: Jones Soda, Radio One, Comcast and ...  -  Dec 28, 2006
American Digital Networks (press release),The very strong trend should continue in 2007, driven by Lunesta and Xopenex MDI. Future long-term growth will depend upon the successful ramping of these

US Stocks Fall as Economic Growth Slows; Copper Miners Drop  -  Dec 21, 2006
BloombergSepracor Inc. jumped $4.94 to $62.31 after Medicare delayed a decision to cut payments for the asthma drug Xopenex. Deutsche Bank and Merrill Lynch also

Business briefs  -  Dec 22, 2006
Worcester Telegram,MARLBORO — Shares of Sepracor Inc. climbed 8.6 percent yesterday after Medicare delayed a decision to cut payment for the asthma drug Xopenex and analysts

Sepracor shares up on CMS analysis  -  Dec 21, 2006
BusinessWeekThe Centers for Medicare and Medicaid Services said it will conduct an analysis of nebulized levalbuterol, which includes the company's Xopenex inhalable

Ahead of the Bell: Sepracor  -  Dec 22, 2006
BusinessWeekThe Centers for Medicare and Medicaid Services plans to review its guidelines for when nebulized levalbuterol, including the company's Xopenex inhalable

Levalbuterol Tartrate Data Presented at American College of ...  -  Nov 28, 2006
DG NewsThis study compared safety and tolerability of cumulative doses of Xopenex HFA (hydrofluoroalkane) MDI (metered-dose inhaler) with those from a racemic

Market Report -- Short Stories (SEPR)  -  Dec 4, 2006
MSN Money...an awakening in the previously sluggish insomnia market, a surge in Xopenex HFA prescriptions, and an apparent delay to Xopenex UDV reimbursement cuts.

Business briefs  -  Dec 22, 2006
Worcester Telegram,MARLBORO — Shares of Sepracor Inc. climbed 8.6 percent yesterday after Medicare delayed a decision to cut payment for the asthma drug Xopenex and analysts

US Stocks Fall as Economic Growth Slows; Copper Miners Drop  -  Dec 21, 2006
BloombergSepracor Inc. jumped $4.94 to $62.31 after Medicare delayed a decision to cut payments for the asthma drug Xopenex. Deutsche Bank and Merrill Lynch also

Sepracor Shares Lunesta Trial Results  -  Dec 4, 2006
Forbes,While Sepracor does not have any cholesterol drugs, other products include the asthma drug Xopenex, chronic obstructive pulmonary disease treatment Brovana,

FDA warns firms to stop making knockoffs of inhalation meds  -  Dec 1, 2006
AAP News (subscription)Since at this time there are no FDA-approved generic forms of Pulmicort Respules, Xopenex or DuoNeb, any generic substitution for these medications is an

Hospital 'chips away' at drug costs  Sep 4, 2006
One example of the cost savings is the switch from the asthma drug Xopenex to a generic. Xopenex costs about $10 to $15 per use ... -Wilmington Morning Star

Respiratory Market to Avoid Collapse - Global Asthma/COPD Sales ...  Sep 13, 2006
...market for short-acting beta2 agonists (SABAs), more than doubling its size. The main beneficiary will be Sepracors Xopenex MDI. -PharmaLive.com

XOPENEX HFA(R) Data Presented at American College of Allergy ...  -  Nov 14, 2006
PipelineReview.com (press release),Today announced that clinical data for XOPENEX HFA(R) (levalbuterol tartrate) Inhalation Aerosol were presented at the American College of Allergy,

Sepracor: positive safety data boost for Xopenex  -  Nov 15, 2006
Pharmaceutical Business ReviewA study demonstrating the safety of Xopenex in a scenario of short-acting beta-agonist (SABA) overdosing, a significant problem among asthma patients,

Xopenex HFA Data Presented at American College of Allergy, Asthma ...  -  Nov 13, 2006
PharmaLive.com (press release),This study compared safety and tolerability of cumulative doses of XOPENEX HFA (hydrofluoroalkane) MDI (metered-dose inhaler) with those from a racemic

Market Report -- Short Stories (SEPR)  -  Dec 4, 2006
MSN Money...an awakening in the previously sluggish insomnia market, a surge in Xopenex HFA prescriptions, and an apparent delay to Xopenex UDV reimbursement cuts.

Sepracor's Second Wind  -  Nov 21, 2006
Barron's (subscription)First, Xopenex MDI [metered-dose inhaler] prescriptions [for treating asthma and chronic obstructive pulmonary disease] should continue to accelerate as we

Sepracor says asthma drug data is favorable  -  Nov 14, 2006
Bizjournals.com,Sepracor Inc. on Monday said a study found the company's asthma drug, Xopenex HFA, produced fewer adverse effects at high doses than another treatment,

Sepracor presents data on asthma drug  -  Nov 13, 2006
BusinessWeek13 12:17 PM ET Drug maker Sepracor Inc. on Monday said a study showed its asthma drug, Xopenex HFA, produced fewer adverse effects at high doses than

Sepracor "outperform," target price raised  -  Nov 20, 2006
newratings.comThis is likely to result in continued acceleration in Xopenex MDI Rxs, with significant growth in 2007 and 2008, the analyst says.

Market Report -- Short Stories (SEPR)  -  Nov 20, 2006
MSN MoneyCredit Suisse upgrades SEPR to Outperform from Neutral saying Xopenex MDI Rxs should continue to accelerate as they expect the transition for inhalers from

Sepracor (SEPR) option implied volatility at 48  -  Nov 17, 2006
StreetInsider.com (subscription),SBSH says "medicare's bill payers have yet to issue a widely anticipated final decision on whether to reduce reimbursement 23-fold for SEPR Xopenex drug.

Sepracor Shares Lunesta Trial Results  -  Dec 4, 2006
Forbes,While Sepracor does not have any cholesterol drugs, other products include the asthma drug Xopenex, chronic obstructive pulmonary disease treatment Brovana,

FDA warns firms to stop making knockoffs of inhalation meds  -  Dec 1, 2006
AAP News (subscription)Since at this time there are no FDA-approved generic forms of Pulmicort Respules, Xopenex or DuoNeb, any generic substitution for these medications is an

While Some Physicians Believe That Inhaled Corticosteroids are ...  -  Nov 20, 2006
Drug Newswire (press release),...tiers and short-acting therapies fall into the first or second tiers of most health plans, but some plans utilize a fourth tier for Sepracor's Xopenex."

Sepracor to restate results back to 2003 due to stock options  Aug 10, 2006
The maker of Lunesta and the asthma medication Xopenex disclosed two months ago that it was among the growing list of companies that the Securities and ... -Boston Globe

Water delivers meds  Aug 7, 2006
Would it shock you to learn that even inhaled meds like Albuterol, Advair and Xopenex are best taken with a full glass of water in order to rinse the throat ... -Denver Post

Commercial Insight: Asthma/COPD - ICS/LABA combinations continue ...  Aug 1, 2006
...market for short-acting beta2 agonists (SABAs), more than doubling its size. The main beneficiary will be Sepracor's Xopenex MDI. -Pharmaceutical Business Review

Sepracor profit jumps on Lunesta, Xopenex sales  Jul 21, 2006
Revenue shot up $264.4 million, from $185.1 million last year, powered largely by sales of its recently-launched sleep aid Lunesta and asthma drug Xopenex. ... -MarketWatch

Sepracor shares tumble over Lunesta sales  Jul 21, 2006
The drug was launched in April last year. Sales of asthma medication Xopenex rose to $117.3 million in the quarter from $83.2 million a year ago. ... -路�社

Sepracor Slips on Lower Analyst Forecast  Jul 10, 2006
The analyst also lowered sales forecasts for the asthma medication Xopenex to $45 million from $90 million for 2006, and to $185 million from $226 million for ... -MSN Money

Sepracor turns attention to antidepressants  Jul 8, 2006
The company, which makes asthma drug Xopenex and is awaiting US approval for a drug to treat smoker's cough, sees its next big opportunity in the ... -Boston Globe

Just rewards?  Jun 25, 2006
Now, the company that plowed through years of losses before the asthma drug Xopenex and the insomnia treatment Lunesta pushed it to profitability in 2005 is ... -Worcester Telegram (subscription)

UPDATE 1-RESEARCH ALERT-JP Morgan cuts Sepracor to "neutral"  Jun 26, 2006
JP Morgan also lowered its earnings estimates for the company, based lower projections for Lunesta, a sleep drug, and asthma drug Xopenex. ... -Reuters

Sepracor Gains Reflect Pfizer Buyout Speculation  Jun 23, 2006
..."We think Lunesta has peak multi-billion dollar sales potential and Sepracor's Xopenex would fit well with Pfizer's respiratory franchise," he said. ... -Forbes



Sepracor falls on bearish Citi note  Mar 27, 2006
...which processes Medicare claims in 20 states, Medicare reimbursements to home respiratory care providers in 20 states would be sharply reduced for Xopenex. ... - BusinessWeek

Bryant children save mom’s life during asthma, heart attack  Mar 18, 2006
She began feeling a little short of breath. She assumed her asthma was acting up and that she would need a breathing treatment of xopenex. ... - Canton Daily Ledger

A warning on asthma drugs  Mar 14, 2006
The medications most likely to be mimicked are Albuterol sulfate, manufactured by Nephron Pharmaceuticals and Warrick Pharmaceuticals; Xopenex, a product of ... - Newsday

Allergy & Asthma Network Mothers of Asthmatics Supports FDA's ...  Mar 14, 2006
HFA. The newest bronchodilator on the market is Xopenex(r) HFA, a brand of levalbuterol, was introduced in December 2005. "Nobody ... - U.S. Newswire



S&P Lifts Sepracor Rating  Feb 13, 2006
S&P cited an improving operating performance from growing sales of the insomnia drug Lunesta and the asthma medication Xopenex, but said that Sepracor "still ... - TheStreet.com

Business briefs  Feb 14, 2006
Ratings Service raised its corporate credit rating on Sepracor to B+ from B based on growing sales of the insomnia drug Lunesta and the asthma treatment Xopenex ... - Worcester Telegram (subscription),

MultiVu Video Feed: Winter Is Here! Tips for Cold Weather Asthma ...  Jan 31, 2006
...asthma plan tailored for the winter. For more information, visit http://www.xopenex.com/. SATELLITE FEEDS: Tuesday, January 31st ... - PR Newswire,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional